SONATA, a physician-led preventive healthcare membership, has launched in New York, San Francisco, and Los Angeles with $7 million in backing from Lux Capital, BoxGroup, Sunflower Capital, and angels including the founders of Ramp and Linear. The $2,500 annual membership combines whole-genome sequencing, 140+ blood biomarkers, DNA methylation analysis, and wearable data integration with unlimited access to a physician-led care team and clinical AI built in-house.
For women’s health specifically, SONATA’s physicians incorporate cycle-phase awareness into hormone testing and follow patients longitudinally – addressing a persistent gap in how hormonal health is evaluated. Hormone levels fluctuate substantially across the menstrual cycle, yet standard testing typically captures a single snapshot without accounting for where a patient is in her cycle, producing results that can be misleading or clinically useless.
The broader pitch is that people now have more health data than ever – from wearables, genetic tests, and biomarker panels – without the clinical guidance or ongoing physician relationship needed to act on it. SONATA runs testing not commonly included in routine primary care and brings the results together with medical history, wearable data, and daily life into a single care model.
“We’re spending more than ever on healthcare, we have more data about ourselves than ever, and yet so many people still feel unwell and are left to manage it on their own,” said co-founder and CEO Sagan Schultz, MD.
“Modern medicine is built on population averages, but no individual is the average,” added co-founder and CTO David Deng. “Someone with an elevated genetic predisposition to a condition may need a different screening schedule, different monitoring, and different targets.”
All clinical decisions remain physician-led, with board-certified physicians responsible for interpretation, diagnosis, prescribing, and care. Schultz was previously the first product manager at Linear and a McKinsey healthcare consultant; Deng was an early engineer at Ramp and worked on Flatiron Health’s clinical genomics team.
At $2,500 a year and available in three cities, SONATA sits firmly in the premium preventive care category – but the cycle-aware hormone testing is a design choice worth noting, given how rarely it appears even in expensive concierge and longevity offerings.
